Trial Profile
Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 07 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 24 Nov 2021 Planned End Date changed to 1 Nov 2023.